UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

Diabetes care, 2007-06, Vol.30 (6), p.1487-1493

2007

Volltextzugriff (PDF)

Pitavastatin is a more sensitive and selective organic anion‐transporting polypeptide 1B clinical probe than rosuvastatin

British journal of clinical pharmacology, 2014-09, Vol.78 (3), p.587-598

2014

Volltextzugriff (PDF)

Effect of renal impairment on the pharmacokinetics of exenatide

British journal of clinical pharmacology, 2007-09, Vol.64 (3), p.317-327

2007

Volltextzugriff (PDF)

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

Regulatory peptides, 2008-11, Vol.151 (1), p.123-129

2008

Volltextzugriff (PDF)

Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment

Clinical and translational science, 2020-05, Vol.13 (3), p.482-490

2020

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes

Endocrine Journal, 2009, Vol.56(8), pp.951-962

2009

Volltextzugriff (PDF)

Can Digital Health Enable Higher Quality Real‐World Evidence‐Based Decisions?

Clinical pharmacology and therapeutics, 2019-07, Vol.106 (1), p.45-46

2019

Volltextzugriff (PDF)

Harnessing the Potential of Emerging Digital Health and Biological Sampling Technologies for Clinical Drug Development: Promise to Reality

Clinical pharmacology and therapeutics, 2018-12, Vol.104 (6), p.1125-1135

2018

Volltextzugriff (PDF)

An Integrated Strategy for Implementation of Dried Blood Spots in Clinical Development Programs

The AAPS journal, 2016-03, Vol.18 (2), p.519-527

2016

Volltextzugriff (PDF)

Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men

Journal of clinical pharmacology, 2006-10, Vol.46 (10), p.1179-1187

2006

Volltextzugriff (PDF)

Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling

Journal of clinical pharmacology, 2018-03, Vol.58 (3), p.294-303

2018

Volltextzugriff (PDF)

Effect of Exenatide on the Steady-State Pharmacokinetics of Digoxin

Journal of clinical pharmacology, 2005-09, Vol.45 (9), p.1032-1037

2005

Volltextzugriff (PDF)

Leveraging Digital Health Technologies and Outpatient Sampling in Clinical Drug Development: A Phase I Exploratory Study

Clinical pharmacology and therapeutics, 2019-01, Vol.105 (1), p.168-176

2019

Volltextzugriff (PDF)

D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography : An Open-label Study in Patients with Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2008-01, Vol.33 (2), p.298-304

2008

Volltextzugriff (PDF)

Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers

British journal of clinical pharmacology, 2013-02, Vol.75 (2), p.549-564

2013

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus

Journal of clinical pharmacology, 2008-12, Vol.48 (12), p.1389-1399

2008

Volltextzugriff (PDF)

Intestinal metabolism: the role of enzyme localization in phenol metabolite kinetics

Drug metabolism and disposition, 2002-05, Vol.30 (5), p.586

2002

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes

ENDOCRINE JOURNAL, 2009, Vol.56 (8), p.951-962

2009

Volltextzugriff (PDF)

The intestinal uptake of phenol from micellar systems does not conform to the aqueous transfer model

Pharmaceutical research, 2000-07, Vol.17 (7), p.839-843

2000

Volltextzugriff (PDF)

Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial

BMC clinical pharmacology, 2012-03, Vol.12 (1), p.8-8, Article 8

2012

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

Clinical pharmacokinetics, 2011, Vol.50 (1), p.65-74

2011

Volltextzugriff (PDF)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

BMC psychiatry, 2010-06, Vol.10 (1), p.45-45, Article 45

2010

Volltextzugriff (PDF)

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy chinese and white volunteers: An open-label trial

Clinical therapeutics, 2010-02, Vol.32 (2), p.365-379

2010

Volltextzugriff (PDF)

Single- and Multiple-Dose Pharmacokinetic, Safety, and Tolerability Profiles of Olanzapine Long-Acting Injection: An Open-Label, Multicenter, Nonrandomized Study in Patients With Schizophrenia

Clinical therapeutics, 2013-12, Vol.35 (12), p.1890-1908

2013

Volltextzugriff (PDF)

Merck's perspective on the implementation of dried blood spot technology in clinical drug development - why, when and how

Bioanalysis, 2013-02, Vol.5 (3), p.341-350

2013

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(29)
Dissertationen
(1)

Sprache

Englisch
(29)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Humans
(22)
Male
(18)
Pharmacology & Pharmacy
(18)
Adult
(13)
Female
(12)
Middle Aged
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(10)
Pharmacokinetics
(10)
Exenatide
(9)
Dose-Response Relationship, Drug
(8)
Pharmacology. Drug Treatments
(8)
Hypoglycemic Agents - Administration & Dosage
(7)
Young Adult
(7)
Aged
(6)
Cross-Over Studies
(6)
Diabetes Mellitus, Type 2 - Drug Therapy
(6)
Hypoglycemic Agents - Pharmacokinetics
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

Pitavastatin is a more sensitive and selective organic anion‐transporting polypeptide 1B clinical probe than rosuvastatin

Effect of renal impairment on the pharmacokinetics of exenatide

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes

Can Digital Health Enable Higher Quality Real‐World Evidence‐Based Decisions?

Harnessing the Potential of Emerging Digital Health and Biological Sampling Technologies for Clinical Drug Development: Promise to Reality

An Integrated Strategy for Implementation of Dried Blood Spots in Clinical Development Programs

Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men

Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling

Effect of Exenatide on the Steady-State Pharmacokinetics of Digoxin

Leveraging Digital Health Technologies and Outpatient Sampling in Clinical Drug Development: A Phase I Exploratory Study

D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography : An Open-label Study in Patients with Schizophrenia

Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus

Intestinal metabolism: the role of enzyme localization in phenol metabolite kinetics

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes

The intestinal uptake of phenol from micellar systems does not conform to the aqueous transfer model

Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy chinese and white volunteers: An open-label trial

Single- and Multiple-Dose Pharmacokinetic, Safety, and Tolerability Profiles of Olanzapine Long-Acting Injection: An Open-Label, Multicenter, Nonrandomized Study in Patients With Schizophrenia

Merck's perspective on the implementation of dried blood spot technology in clinical drug development - why, when and how

Suchergebnisse filtern